N/A
Completed N=33
Virtual Reality for Outpatient Cancer Pain Management
Source: ClinicalTrials.gov NCT05442866 ↗Enrolled (actual)
33
Serious AEs
6.1%
Results posted
May 2025
Primary outcomePrimary: Self-reported Pain Score — -0.3 score on a scale, measured each week
Summary
This is a non-randomized, unblinded dose-titration study to evaluate different "doses" of virtual reality to impact moderate-to-severe pain in patients living with cancer. After consenting to participate, in addition to usual pharmacologic pain management, participants will receive 1 week of VR daily for 10 minutes per session, then 1 week of VR twice a day for 10 minutes per session, then 1 week of VR use as desired by the participants.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Self-reported Pain Score |
-0.3 | — |
| SECONDARY PROMIS Pain Interference Short Form |
-1.5 | — |
| SECONDARY Number of As-needed Opioid Doses Per Day |
1.6; 1.5; 1.6 | — |
| SECONDARY Satisfaction With Overall Pain Management |
0.7 | — |
| SECONDARY Satisfaction With Virtual Reality Intervention Over Previous 7 Days |
9.5 | — |
| SECONDARY Preferences for Virtual Reality Thematic Content (Measured Once, With no Comparison) |
14; 7; 1 | — |
Eligibility Criteria
Inclusion Criteria
- Age 18 years and older
- Have diagnosis of cancer (any type)
- Report moderate-severe pain related to cancer or cancer treatment at baseline
- Able to provide consent
Exclusion Criteria
- Already use VR for personal use
- Have intractable nausea/vomiting, history of motion sickness, history of seizures or epilepsy
- Have cranial structure abnormalities that prevent use of VR headset
- Currently enrolled in a palliative care or pain management study
Data sourced from ClinicalTrials.gov (NCT05442866). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.